An exploratory phase II, randomised, double-blind, placebo-controlled, parallel-group study investigating the efficacy and safety of Sepranolone in women with menstrual migraine
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2019
Price : $35 *
At a glance
- Drugs Sepranolone (Primary)
- Indications Menstrual migraine
- Focus Proof of concept; Therapeutic Use
- Sponsors Asarina Pharma
- 29 Jun 2019 Status changed from planning to recruiting.
- 07 Sep 2018 New trial record
- 27 Aug 2018 According to Asarina Pharma media release, trial is expected to start in the first half of 2019.